Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

CHICAGO--(BUSINESS WIRE)--Jun 7, 2007 - Clinical results from a Phase II study presented for the first time at the American Headache Society (AHS) annual meeting showed that MK-0974, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved migraine pain relief two hours after dosing compared to placebo, and the relief was sustained through 24 hours. MK-0974 was generally well tolerated in the study. Responses specific to other measures, such as migraine-associated symptoms, functional disability and use of additional rescue medications also were reported. MK-0974 is Merck's investigational medicine in Phase III clinical development for the acute treatment of migraine in adults and, if approved, may be the first in a new class of migraine treatments since the approval of the first triptan drug in 1991.

"The findings of this early-stage trial demonstrate the therapeutic potential of MK-0974 for the acute treatment of migraines," said Tony Ho, M.D., senior director of Clinical Neuroscience, Merck Research Laboratories. "Larger clinical trials, such as those now underway, will provide more insight into the efficacy and safety profile of MK-0974."

About MK-0974

MK-0974 is an antagonist of the receptor for CGRP, a primary neuropeptide involved in the pathophysiology of migraine. CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the transmission of migraine pain. During migraine attacks, CGRP activates these receptors and facilitates the transmission of pain impulses. MK-0974 blocks the binding of CGRP to receptors within these areas and thereby is believed to inhibit the transmission of pain signals that lead to migraine headaches.

Study design

The findings being presented are from a randomized, double-blind, placebo- and active-controlled dose-ranging clinical trial in patients wi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:12/24/2014)... BUFFALO, N.Y. , Dec. 24, 2014 ... been dosed with KX2-361 at Roswell Park Cancer Institute. ... a small molecule drug that has shown potent inhibitory ... lines, including those that are resistant to Temozolomide (T98G), ... malignant glioma. In a well-established brain tumor mouse model, ...
(Date:12/24/2014)... and FARMINGTON, Conn. , ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of 2,050,000 shares of its common ... shares of its common stock.  Funds under the ...
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... infringement action against Chinese medical device manufacturer BMC Medical Co., ... today that BMC,s masks listed below infringe ResMed,s patents, and ... these masks in the United States : ... nasal mask , Willow nasal pillows mask , ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... Sysmex America, Inc. (SAI), a leading medical ... announced that Laboratory Corporation of America® Holdings (LabCorp®) ... five-year agreement for Sysmex America, Inc. to provide ... laboratories.  Implementation of the systems has been completed. ...
... 10 Varian Medical Systems (NYSE: ... linear accelerator for fast, powerful and efficient cancer treatments ... exhibition in Barcelona next week. A fully-featured TrueBeam system ... annual ESTRO meeting (Booth No. 320). TrueBeam ...
Cached Medicine Technology:Sysmex America Announces LabCorp Hematology Automation Agreement 2Varian Medical Systems Spotlights TrueBeam Treatment System for First Time in Europe at ESTRO 2010, September 12-16, Barcelona 2Varian Medical Systems Spotlights TrueBeam Treatment System for First Time in Europe at ESTRO 2010, September 12-16, Barcelona 3
(Date:12/24/2014)... December 24, 2014 New studies reveal that ... hearing loss related depression (March 6, 2014, JAMA Otolaryngology*). And ... hearing loss (about 50 percent according to recent polls) facing ... on how a person feels and relates to the world. ... improvements are also made by way of:, , ...
(Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... ( http://www.xareltolawsuit2015.com/ ) that allege the blood thinner ... complications has outlined a leadership structure for the ... Order dated December 17th, the Court plans to ... the parties and also plans on appointing a ...
(Date:12/24/2014)... December 25, 2014 Today, Yunx.co.uk, a ... evening dresses and other special occasion outfits, unveils ... models are offered at discounted prices, up to 80% ... young ladies with their fashionable designs, gorgeous looks and ... exception. The business is devoted to designing and offering ...
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter ... bisexual men who have abstained from sex for one year will ... new federal policy that would reverse a 31-year ban on donations ... and Drug Administration announced Tuesday its intention to release a new ... to blood donations from gay men. The FDA is changing ...
Breaking Medicine News(10 mins):Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3
... ... tied to the loss of independence, and at the root of that ... accompany aging. But staying active is worth the effort, according to Home ... underscores the mental and physical value of being fit, Home Instead launched ...
... Lightweight, cordless design ... ... pounds and with a sound level of only 58 dBA, the new Adgility™ XPB ... Powered by a lithium ion battery with 30 minutes of cleaning time, the Adgility XPB ...
... better survival rates a year after intensive care , TUESDAY, ... above the level ordinarily regarded as dangerous -- is a ... intensive care unit because of chest pains that indicate a ... involved 119,151 people admitted to ICUs for chest pain between ...
... RALEIGH, N.C. , March 23 ... non-profit organization dedicated to exposing government corruption and educating ... allegations of public corruption related to the passage or ... into law today.   Citizens nationwide can anonymously and ...
... issued the following statement on the health reform legislation that was signed into law today by President Obama:   , ... , , ... ... ...
... to reduce healthcare costs edited by Stephan Kudyba, an ... be released early this May. Healthcare Informatics: Improving Efficiency ... technologies and information management by healthcare providers to increase ... The text describes evolving areas of ...
Cached Medicine News:Health News:Senior Fear Factors: What Aging Americans Fear Most 2Health News:Senior Fear Factors: What Aging Americans Fear Most 3Health News:Advance Introduces the Adgility™ XPB Battery Backpack Vacuum – the Lightest in the Industry, 2Health News:When Heart Is in Crisis, High Blood Pressure a Good Sign 2Health News:When Heart Is in Crisis, High Blood Pressure a Good Sign 3Health News:Foundation for Ethics in Public Service, Inc. is Available to Review Allegations of Fraud or Corruption Related to The Healthcare Reform Bill 2Health News:Alzheimer's Foundation of America Hails Significant Provisions for Dementia Community in Health Reform Law 2Health News:Alzheimer's Foundation of America Hails Significant Provisions for Dementia Community in Health Reform Law 3Health News:Alzheimer's Foundation of America Hails Significant Provisions for Dementia Community in Health Reform Law 4Health News:Decreasing health-care costs is focus of new informatics book by NJIT professor 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: